---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-018160"
form_type: "8-K"
ticker: "LCTX"
cik: "0000876343"
company_name: "Lineage Cell Therapeutics, Inc."
filed_at: "2023-05-18T23:59:59+00:00"
generated_at: "2026-06-14T21:55:00.280825+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Lineage Cell Therapeutics updates shelf offering to sell up to $38.9M in common shares

## Summary
- Offering up to $38,856,704 of common shares under previously effective Form S-3 registration statement.
- Prospectus supplement filed May 18, 2023, updating the Controlled Equity Offering agreement with Cantor Fitzgerald & Co.
- Legal opinion from Sheppard, Mullin, Richter & Hampton LLP on share validity included as exhibit.

## SEC filing metadata
- accession: 0001493152-23-018160
- form_type: 8-K
- ticker: LCTX
- cik: 0000876343
- company_name: Lineage Cell Therapeutics, Inc.
- filed_at: 2023-05-18T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/876343/000149315223018160/0001493152-23-018160-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/876343/000149315223018160/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-018160
- JSON: https://secwatch.observer/filing/0001493152-23-018160.json
- Plain text: https://secwatch.observer/filing/0001493152-23-018160.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.